Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Daiichi Sankyo has selected Ranbaxy to market its four products including Cravit (levofloxacin) tab and Cravit IV in Singapore.
Subscribe to our email newsletter
Previously those products were marketed by ‘Kyowa Kyowa Hakko Bio, reported thehindubusinessline.com.
Daiichi Sankyo and Kyowa Hakko Bio had agreed to transfer the marketing rights of the products from Kyowa Hakko Bio to Ranbaxy, early this year.
Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class which is indicated for the treatment of range of infections.
The news paper has quoted Ranbaxy managing director Arun Sawhney as saying that they will use their marketing strengths to offer medicines from Daiichi Sankyo in ASEAN region, beginning with Singapore.